CompletedPhase 4

Efficacy of IARULIL® in the Treatment of Recurrent Cystitis Refractory to Escherichia Coli Extract

South Korea105 participantsStarted 2014-01

Plain-language summary

The purpose of this study is to evaluate the efficacy of Combined Intravesical Therapy With Hyaluronic Acid and Chondroitin Sulphate in the Treatment of Recurrent Cystitis Refractory to Escherichia Coli Extract

Who can participate

Age range20 Years – 80 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. female patients aged between 20 and 80 years
✓. Patients diagnosed with recurrent cystitis and treated with Escherichia Coli Extract
✓. Patients with Refractory to Escherichia Coli Extract treatment

Exclusion criteria

✕. child-bearing potential, pregnant or nursing women.
✕. Residual urine volume \>100ml
✕. genitourinary tuberculosis or cancer / anatomical abnomality of genitourinary tract / neurologic abnormality of low urinary tract.
✕. history of treatment for acute cystitis within 2weeks.

What they're measuring

The number of recurrence for recurrent cystitis

Timeframe: 12 months

Trial details

NCT IDNCT02366676

SponsorSamsung Medical Center

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2018-01

View on ClinicalTrials.gov More Recurrent Cystitis trials